Literature DB >> 17451199

Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.

Pascal Veillon1, Christopher Payan, Hélène Le Guillou-Guillemette, Catherine Gaudy, Françoise Lunel.   

Abstract

AIM: To evaluate the implication of substitutions in the hepatitis C virus (HCV) non-structural 5A (NS5A) protein in the resistance of HCV during mono-interferon (IFN) or combined IFN-ribavirin (IFN-R) therapy. Although NS5A has been reported to interact with the HCV RNA-dependent RNA polymerase, NS5B, as well as with many cellular proteins, the function of NS5A in the life cycle of HCV remains unclear.
METHODS: HCV quasispecies were studied by cloning and sequencing of sequential isolates from patients infected by HCV genotype 1b. Patients were treated by IFN-alpha2b for 3 mo followed by IFN-alpha2b alone or combined IFN-R therapy for 9 additional months. Patients were categorized into two groups based on their response to the treatments: 7 with sustained virological response (SVR) (quasispecies = 150) and 3 non-responders (NR) to IFN-R (quasispecies = 106).
RESULTS: Prior to treatment, SVR patients displayed a lower complexity of quasispecies than NR patients. Most patients had a decrease in the complexity of quasispecies during therapy. Analysis of amino acids substitutions showed that the degree of the complexity of the interferon sensitivity-determining region (ISDR) and the V3 domain of NS5A protein was able to discriminate the two groups of patients. Moreover, SVR patients displayed more variability in the NS5A region than NR patients.
CONCLUSION: These results suggest that detailed molecular analysis of the NS5A region may be important for understanding its function in IFN response during HCV 1b infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17451199      PMCID: PMC4146993          DOI: 10.3748/wjg.v13.i8.1195

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  45 in total

1.  Rapid and simple method for purification of nucleic acids.

Authors:  R Boom; C J Sol; M M Salimans; C L Jansen; P M Wertheim-van Dillen; J van der Noordaa
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

2.  Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy.

Authors:  M Kurosaki; N Enomoto; T Murakami; I Sakuma; Y Asahina; C Yamamoto; T Ikeda; S Tozuka; N Izumi; F Marumo; C Sato
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

3.  The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon.

Authors:  S J Polyak; J B Nousbaum; A M Larson; S Cotler; R L Carithers; D R Gretch
Journal:  J Infect Dis       Date:  2000-07-14       Impact factor: 5.226

4.  From RNA to quasispecies: a DNA polymerase with proofreading activity is highly recommended for accurate assessment of viral diversity.

Authors:  Isabelle Malet; Magali Belnard; Henri Agut; Annie Cahour
Journal:  J Virol Methods       Date:  2003-05       Impact factor: 2.014

5.  Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome.

Authors:  Catherine Gaudy; Marie Lambelé; Alain Moreau; Pascal Veillon; Francoise Lunel; Alain Goudeau
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

6.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.

Authors:  N Enomoto; I Sakuma; Y Asahina; M Kurosaki; T Murakami; C Yamamoto; Y Ogura; N Izumi; F Marumo; C Sato
Journal:  N Engl J Med       Date:  1996-01-11       Impact factor: 91.245

7.  Efficacy and changes of the nonstructural 5A GENE by prolonged interferon therapy for patients with hepatitis C virus genotype 1b and a high level of serum HCV-RNA.

Authors:  Y Arase; K Ikeda; K Chayama; N Murashima; A Tsubota; Y Suzuki; S Saitoh; M Kobayashi; M Kobayashi; M Kobayashi; H Kumada
Journal:  Intern Med       Date:  1999-06       Impact factor: 1.271

8.  Why is the interferon sensitivity-determining region (ISDR) system useful in Japan?

Authors:  I Nakano; Y Fukuda; Y Katano; S Nakano; T Kumada; T Hayakawa
Journal:  J Hepatol       Date:  1999-06       Impact factor: 25.083

9.  Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection.

Authors:  G Squadrito; M E Orlando; I Cacciola; M G Rumi; M Artini; A Picciotto; O Loiacono; R Siciliano; M Levrero; G Raimondo
Journal:  J Hepatol       Date:  1999-06       Impact factor: 25.083

10.  Mutations in the NS5A region do not predict interferon-responsiveness in american patients infected with genotype 1b hepatitis C virus.

Authors:  R T Chung; A Monto; J L Dienstag; L M Kaplan
Journal:  J Med Virol       Date:  1999-08       Impact factor: 2.327

View more
  11 in total

Review 1.  The quasispecies nature and biological implications of the hepatitis C virus.

Authors:  Sarah L Fishman; Andrea D Branch
Journal:  Infect Genet Evol       Date:  2009-08-08       Impact factor: 3.342

2.  Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy.

Authors:  James Lara; Guoliang Xia; Mike Purdy; Yury Khudyakov
Journal:  J Virol       Date:  2011-01-19       Impact factor: 5.103

3.  The Relationship Between HCV-NS5A Gene Mutations and Resistance to Combination Therapy in Patients with HCV- Genotype 1-B.

Authors:  Hamed Esmaeil Lashgarian; Ali Valibeik; Abdolrazagh Marzban; Maryam Karkhane; Kiana Shahzamani
Journal:  Rep Biochem Mol Biol       Date:  2021-07

Review 4.  Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.

Authors:  Shinya Maekawa; Nobuyuki Enomoto
Journal:  J Gastroenterol       Date:  2009       Impact factor: 7.527

Review 5.  Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy.

Authors:  H Le Guillou-Guillemette; S Vallet; C Gaudy-Graffin; C Payan; A Pivert; A Goudeau; F Lunel-Fabiani
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

Review 6.  Natural products as promising drug candidates for the treatment of hepatitis B and C.

Authors:  Carolin Wohlfarth; Thomas Efferth
Journal:  Acta Pharmacol Sin       Date:  2008-12-08       Impact factor: 6.150

7.  Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.

Authors:  Severine Margeridon-Thermet; Robert W Shafer
Journal:  Viruses       Date:  2010-12-01       Impact factor: 5.048

8.  Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections.

Authors:  Celia Perales; Rubén Agudo; Hector Tejero; Susanna C Manrubia; Esteban Domingo
Journal:  PLoS Pathog       Date:  2009-11-13       Impact factor: 6.823

9.  Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.

Authors:  P Muñoz de Rueda; J Casado; R Patón; D Quintero; A Palacios; A Gila; R Quiles; J León; A Ruiz-Extremera; J Salmerón
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

10.  Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy.

Authors:  Nathan A Cannon; Maureen J Donlin; Xiaofeng Fan; Rajeev Aurora; John E Tavis
Journal:  PLoS One       Date:  2008-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.